T2 Biosystems Inc

NASDAQ:TTOO  
0.17
-0.01 (-2.86%)
4:22:13 PM EDT: $0.17 0.00 (-1.73%)
Products

T2 Biosystems - On May 23, 2022, FDA Informed Co That Application For Breakthrough Device Designation For Co's T2biothreat Panel Had Been Denied

Published: 05/24/2022 21:44 GMT
T2 Biosystems Inc (TTOO) - T2 Biosystems - on May 23, 2022, FDA Informed Co That Application for Breakthrough Device Designation for Co's T2biothreat Panel Had Been Denied.
T2 Biosystems - Co is Continuing to Conduct U.S. Clinical Trial for T2biothreat Panel.
T2 Biosystems - U.S. Clinical Trial for T2biothreat Panel is Expected to Be Completed in 2022.
T2 Biosystems - Co Believes Data From T2biothreat Trial May Enable Filing Submission for FDA Clearance During 2022.
Further Company Coverage: Ttooo ((reuters.
Briefs@thomsonreuters.
Com;)).